
Built for testing laboratories, QBench is a cloud LIMS that brings samples, workflows, lab data, inventory, reporting, quality processes, and client interactions into a single system.
From order placement through sample processing, results, and automated reporting, QBench supports every stage of lab operations. Lab teams configure their own workflows, data fields, and automation rules, so the software fits existing processes instead of forcing new ones. When requirements shift, labs can adjust fields, processes, and automations without depending heavily on custom code.
Instruments, software, and outside systems connect to QBench through file parsers and a robust API, which moves data automatically and limits repetitive entry and transcription mistakes. For reporting beyond the LIMS, labs can connect QBench to Tableau, Power BI, Domo, or Looker via REST API.
What labs get with QBench:
Sample and workflow management
Configurable workflows and custom data fields
Workflow automation
Instrument and system integrations
File parsing and API connectivity
Inventory management
A client portal
Automated reporting
Analytics and operational insights
Connections to Tableau, Power BI, Domo, and Looker
A built-in Quality Management System (QMS)
Because it runs in the cloud, lab teams get secure access to their data, workflows, quality management, and reporting in one centralized platform. Implementation and ongoing guidance come from a team that includes former bench scientists who understand laboratory workflows.
Learn more

Qualio is a purpose-built quality and compliance platform for life sciences companies operating in complex, high-stakes regulatory environments. Medical device, SaMD, biotech, and pharma teams use Qualio to replace fragmented eQMS tools, spreadsheets, and consultant-driven audits with a single, validated system that delivers continuous audit and inspection readiness.
Qualio combines a modern eQMS with Compliance Intelligence—an AI-driven layer that continuously evaluates how well real operating data aligns with regulatory requirements. Instead of treating audits as one-off events, teams gain always-on visibility into compliance coverage, risk exposure, and readiness across FDA, ISO, EU MDR, GxP, and software-intensive standards.
Core quality workflows—document control, training, CAPA, change management, supplier quality, and design controls—are directly connected to regulatory obligations and objective evidence. Deep integrations with Jira, Azure DevOps, GitHub, TestRail, and Salesforce automatically capture proof from development and operational systems, eliminating manual evidence gathering and reducing compliance drag on engineering teams.
Compliance Intelligence runs multi-standard gap analysis in under an hour, flags emerging risks before they become findings or 483s, and maps reusable evidence across frameworks to accelerate submissions and market expansion. All insights are explainable and traceable back to specific clauses and internal policies, supporting validation and audit expectations.
The result: audit readiness in weeks instead of months, fewer fire drills, faster launches, and lower long-term compliance cost. Qualio turns compliance from a reactive burden into a predictable, scalable system.
Learn more
Claude Mythos 5.1
Claude Mythos 5.1 represents Anthropic's latest advancement in the Mythos-class of models, tailored for sophisticated applications in cybersecurity, biology, scientific investigation, programming, and extensive knowledge-oriented tasks. While it shares the same foundational architecture as Claude Fable 5.1, it is differentiated by unique safety measures: Fable 5.1 is widely accessible, whereas Mythos 5.1 is limited to select trusted access programs designed with specific safeguards for cybersecurity and life sciences research. This model establishes a new benchmark in performance for autonomous coding and showcases unparalleled cyber capabilities among all Anthropic models released thus far. In the realm of scientific research, Mythos 5.1 can effectively handle specialized tools and intricate workflows related to molecular design, computational biology, and various technical fields. During testing by Anthropic, it successfully engineered high-affinity protein binders for multiple targets, achieving its highest recorded hit rate to date. Additionally, it demonstrated proficiency in optimizing seven different open-source deep learning models focused on protein and genomics. By pushing the boundaries of what is possible, Mythos 5.1 is positioned to make significant contributions to future research and development endeavors.
Learn more
3decision
3decision® serves as a cloud-based repository for protein structures, focusing on efficient management of structural data and offering sophisticated analytics to support teams involved in the discovery of small molecules and biologics, thereby expediting the process of structure-based drug design.
The platform consolidates and standardizes both experimental and computational protein structures sourced from publicly available databases such as RCSB PDB and AlphaFoldDB, in addition to proprietary datasets, and accommodates formats like PDBx/mmCIF and ModelCIF. This comprehensive approach guarantees seamless access to a variety of structural formats including X-Ray, NMR, cryo-EM, and modeled structures, thereby promoting collaboration and bolstering research initiatives.
In addition to its storage capabilities, 3decision® enhances each entry with valuable metadata and sequence information, which encompasses details on protein-ligand interactions, antibody annotations, and specifics about binding sites. Equipped with advanced analytical instruments, the platform is capable of pinpointing druggable sites, evaluating off-target risks, and facilitating comparisons of binding sites, which collectively transform extensive structural datasets into practical insights that can drive research forward.
Furthermore, its cloud-based architecture fosters enhanced collaboration among research teams, making it easier for scientists to share findings and insights, ultimately leading to more innovative approaches in drug discovery and development.
Learn more